百奧泰生(sheng)(sheng)物(wu)制(zhi)藥(yao)股份(fen)有(you)限(xian)公司是(shi)一(yi)家以創(chuang)新藥(yao)和生(sheng)(sheng)物(wu)類似藥(yao)研發為核心的創(chuang)新型生(sheng)(sheng)物(wu)制(zhi)藥(yao)企業。公司秉承“創(chuang)新只為生(sheng)(sheng)命”的理(li)念,基于現代生(sheng)(sheng)物(wu)科學的研究發現,致力于開(kai)發新一(yi)代創(chuang)新藥(yao)和生(sheng)(sheng)物(wu)類似藥(yao),用于治療腫瘤、自身免疫性(xing)疾病、心血管疾病以及(ji)(ji)其(qi)它危及(ji)(ji)人類生(sheng)(sheng)命或健(jian)康的重(zhong)大(da)疾病。公司于2020年2月(yue)正(zheng)式在上(shang)交所科創(chuang)板掛(gua)牌交易,股票(piao)代碼為688177。
公(gong)(gong)(gong)司(si)(si)(si)有(you)二十余(yu)個(ge)主要在研(yan)產品。格(ge)樂立®是(shi)公(gong)(gong)(gong)司(si)(si)(si)自(zi)主開(kai)(kai)發(fa)的(de)(de)阿(a)達木單(dan)(dan)抗注(zhu)射液,已獲得國(guo)家藥監(jian)局(ju)批準(zhun)上市,是(shi)獲批上市的(de)(de)國(guo)產阿(a)達木單(dan)(dan)抗,可治療(liao)類風(feng)濕關(guan)節(jie)炎(yan)(yan)、強直性(xing)(xing)脊柱炎(yan)(yan)、銀屑病等自(zi)身免疫性(xing)(xing)疾(ji)病。格(ge)樂立®的(de)(de)成(cheng)功(gong)上市是(shi)公(gong)(gong)(gong)司(si)(si)(si)全(quan)體員工共同(tong)努(nu)力(li)的(de)(de)成(cheng)果,是(shi)多(duo)位臨(lin)(lin)床專家合作(zuo)支持,以及許多(duo)自(zi)身免疫疾(ji)病患(huan)者共同(tong)參與的(de)(de)成(cheng)功(gong)典范。公(gong)(gong)(gong)司(si)(si)(si)自(zi)主開(kai)(kai)發(fa)的(de)(de)貝伐(fa)珠單(dan)(dan)抗正(zheng)在開(kai)(kai)展國(guo)際多(duo)中心III期臨(lin)(lin)床研(yan)究(jiu),擬(ni)治療(liao)轉移性(xing)(xing)結直腸癌(ai)、晚(wan)期非(fei)鱗(lin)狀非(fei)小(xiao)細胞(bao)肺癌(ai)等癌(ai)癥。公(gong)(gong)(gong)司(si)(si)(si)自(zi)主開(kai)(kai)發(fa)的(de)(de)托珠單(dan)(dan)抗正(zheng)在進行國(guo)際多(duo)中心III期臨(lin)(lin)床研(yan)究(jiu),擬(ni)治療(liao)類風(feng)濕關(guan)節(jie)炎(yan)(yan)、全(quan)身型幼年特發(fa)性(xing)(xing)關(guan)節(jie)炎(yan)(yan)等自(zi)身免疫性(xing)(xing)疾(ji)病。公(gong)(gong)(gong)司(si)(si)(si)另(ling)有(you)多(duo)個(ge)創(chuang)新抗體在研(yan)藥物處于臨(lin)(lin)床前(qian)研(yan)究(jiu)階段。
公(gong)司(si)的(de)(de)抗(kang)體產(chan)業園位于廣州市永(yong)和開發區,占地面積約4萬平(ping)米,目前已(yi)完成(cheng)建設并投入(ru)使用(yong)的(de)(de)有2臺3500L不銹鋼生(sheng)物反應(ying)器(qi)(qi)及(ji)其配套的(de)(de)下游純(chun)(chun)化(hua)(hua)生(sheng)產(chan)線(xian)(xian),3臺500L一次性(xing)反應(ying)器(qi)(qi)及(ji)其配套的(de)(de)下游純(chun)(chun)化(hua)(hua)生(sheng)產(chan)線(xian)(xian),1臺200L抗(kang)體藥物偶聯體反應(ying)釜及(ji)其配套的(de)(de)隔離(li)器(qi)(qi)系(xi)統及(ji)純(chun)(chun)化(hua)(hua)生(sheng)產(chan)線(xian)(xian),1條西林瓶無菌(jun)注射(she)(she)液洗(xi)烘灌(guan)(guan)封聯動生(sheng)產(chan)線(xian)(xian),1條預(yu)灌(guan)(guan)封注射(she)(she)器(qi)(qi)灌(guan)(guan)裝生(sheng)產(chan)線(xian)(xian)和1條凍干(gan)生(sheng)產(chan)線(xian)(xian)。公(gong)司(si)正在(zai)繼續擴大單抗(kang)原液產(chan)能,以滿足多個臨床在(zai)研產(chan)品(pin)的(de)(de)產(chan)業化(hua)(hua)需求。
公(gong)司獲得過多項(xiang)(xiang)“十二五”“十三(san)五”國家重(zhong)大新藥創制科技(ji)重(zhong)大專項(xiang)(xiang)立項(xiang)(xiang)支持;被認定為廣(guang)東省(sheng)(sheng)(sheng)新型研(yan)發機構、廣(guang)東省(sheng)(sheng)(sheng)工(gong)程技(ji)術(shu)研(yan)究中心(xin)、廣(guang)東省(sheng)(sheng)(sheng)抗體藥物(wu)偶(ou)聯生物(wu)醫藥工(gong)程實(shi)驗室(廣(guang)東省(sheng)(sheng)(sheng)工(gong)程實(shi)驗室)。
公司始終以患者的(de)福祉作為首(shou)要核心價值,通過(guo)創(chuang)新研發(fa)為患者提供(gong)安全(quan)、有(you)效、可(ke)負擔的(de)優質藥物,以滿足亟待解決(jue)的(de)治療需求(qiu)。